Cynata Therapeutics (ASX:CYP) says it has secured firm commitments for an institutional placement of approximately 6 million new shares at $0.25 per share, raising about $1.5 million before costs.
The company said the placement was supported by new and existing institutional and professional investors and was led by Taylor Collison and Euroz Hartleys.
The cash injection is intended to strengthen Cynata’s runway through two near-term clinical milestones and to position the company for commercial partnering and regulatory engagement after results are released.
Cynata is expecting final results from its Phase 3 osteoarthritis trial of CYP 004 in May 2026 and top-line data from its randomised double blind Phase 2 trial of CYP 001 in acute graft versus host disease in June 2026.
The Phase 3 osteoarthritis study is the world’s largest MSC-based osteoarthritis trial, enrolling 321 patients and managed by the University of Sydney with NHMRC funding (slide page 13).
Cynata markets Cymerus as a next-generation manufacturing approach that converts a single blood donation into an iPSC master cell bank to produce consistent MSCs at scale.
The company also points to prior clinical signals that support further development. Phase 1 data for CYP 001 in steroid-resistant aGvHD showed encouraging survival and response metrics and a favourable safety profile.
Chief Executive Officer Dr Kilian Kelly framed the placement as a cautious and strategic step ahead of the readouts, saying, “The Board considered it prudent to undertake a small and strategically sized placement ahead of our two upcoming clinical trial readouts. By only raising a small amount now, we have minimised dilution while strengthening Cynata's cash runway. We are planning for success in our upcoming Phase 3 osteoarthritis and Phase 2 acute GvHD readouts, and we will now be better placed to progress commercial partnering discussions and regulatory engagement, without losing momentum. I would like to thank our existing shareholders for their continued support and welcome our new investors as we approach this pivotal period for the Company.”